+91 44 2496 8000 info@caplinpoint.net

News

Caplin Steriles receives EIR from US FDA

Caplin Steriles Ltd, a subsidiary of Caplin Point Laboratories Ltd, today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its injectable and ophthalmic manufacturing unit located near Chennai. The unit underwent an inspection from US FDA during May 22nd ~ May 31st and…

Read More »

Caplin Point listed on Forbes Asia’s “200 Best Under a Billion” for 2023

Caplin Point Laboratories Ltd has been recognized in Forbes Asia’s 200 Best Under a Billion list for the year 2023, a compilation that underscores companies’ sustained and robust performance across critical benchmarks. Carefully selected from a substantial pool of more than 20,000 publicly traded companies across the Asia-Pacific region, the chosen 200 enterprises showcase annual…

Read More »

CAPLIN STERILES GETS USFDA APPROVAL FOR CISATRACURIUM BESYLATE INJECTION

Chennai, June 12, 2023: Caplin Steriles Limited (Caplin), a Subsidiary company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Cisatracurium Besylate Injection USP, 10 mg/5 mL (2 mg/mL) and 200 mg/20 mL…

Read More »

CAPLIN STERILES GETS USFDA APPROVAL FOR KETOROLAC TROMETHAMINE INJECTION

Chennai, May 12, 2023: Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ketorolac Tromethamine Injection USP, 15 mg/mL and 30 mg/mL Single-dose Vial, a generic…

Read More »

CAPLIN STERILES GETS USFDA APPROVAL FOR THIAMINE HYDROCHLORIDE INJECTION

Chennai, March 08, 2023: Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Thiamine Hydrochloride Injection USP, 200 mg/2 mL (100 mg/mL) Multi-dose Vial, a generic…

Read More »

CAPLIN STERILES GETS USFDA APPROVAL FOR ROCURONIUM BROMIDE INJECTION

Chennai, March 03, 2023: Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT) Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Rocuronium Bromide Injection, 10 mg/mL in 5 mL and…

Read More »

CAPLIN STERILES GETS USFDA APPROVAL FOR CARBOPROST TROMETHAMINE INJECTION USP

Chennai, February 14, 2023: Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT) Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carboprost Tromethamine Injection USP, 250 mcg/mL Single-dose Vials, a…

Read More »

Caplin Point receives Hindustan Chamber of Commerce – Business Excellence Awards 2022

Chennai, Aug 27 (UNI) The Hindustan Chamber of Commerce (HCC) today celebrated its Chamber Day with the theme “Tamil Nadu towards USD one Trillion Economy” where the Business Excellence and Humanity awards were presented. Tamil Nadu Industries Minister Thangam Thennarasu, who participated in the Chamber Day event and presented the awards, said Chief Minister M.K….

Read More »

Caplin Point Laboratories is listed on “Forbes Asia’s 200 Best Under a Billion companies” for the 5th time in the last 9 years

Happy to announce that Caplin Point Laboratories is listed on “Forbes Asia’s 200 Best Under a Billion companies” for the 5th time in the last 9 years. This remarkable achievement is a testament to our consistent growth and razor-sharp focus on benchmark cash flows and profitability. Accomplishment of 5th year on the list stands unprecedented…

Read More »